Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

393
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
393
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

438
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
438
Focusing of Light in the Eye01:16

Focusing of Light in the Eye

2.5K
Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
2.5K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

693
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
693
Glaucoma: Overview01:25

Glaucoma: Overview

508
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
508
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

1.2K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Primary Open-Angle Glaucoma among Black and Latinx Populations: Exploring Racial Disparities in the United States.

Journal of racial and ethnic health disparities·2026
Same author

Comparison of Electroconvulsive Therapy Seizure Outcomes When Using Methohexital Versus Propofol: A Brief Retrospective Report.

The journal of ECT·2026
Same author

The impact of contact lenses on binocular vision in patients with Keratoconus.

Journal of optometry·2026
Same author

Ophthalmic manifestations in preterm children without retinopathy of prematurity: A review.

Survey of ophthalmology·2026
Same author

Early Detection of Cystoid Macular Edema in Retinitis Pigmentosa Using Longitudinal Deep Learning Analysis of OCT Scans.

Diagnostics (Basel, Switzerland)·2026
Same author

Detection of cystoid macular edema in patients with retinitis pigmentosa based on deep learning.

International journal of retina and vitreous·2025

相关实验视频

Updated: Jun 7, 2025

Author Spotlight: Exploring Press Needle Efficacy and Underlying Molecular Pathways
05:26

Author Spotlight: Exploring Press Needle Efficacy and Underlying Molecular Pathways

Published on: April 12, 2024

1.3K

控制近视使用低剂量阿特罗宾眼药眼滴控制近视

Zhale Rajavi1,2,3, Bahareh Kheiri4,5, Kourosh Sheibani6

  • 1Negah Aref Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Journal of current ophthalmology
|November 18, 2024
PubMed
概括

低剂量氨酸 (0.01%) 在两年内有效减缓近视的进展和轴延伸,超过50%的儿科患者. 这种治疗推用于儿童和青少年的渐进近视,并发症最小.

关键词:
亚特罗皮因是一种类型的亚特罗皮因.轴长 轴长 轴长 轴长 轴长低剂量的低剂量近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近视近控制近视的进展 控制近视的进展

更多相关视频

Inducement and Evaluation of a Murine Model of Experimental Myopia
07:20

Inducement and Evaluation of a Murine Model of Experimental Myopia

Published on: January 22, 2019

9.8K
Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity
05:46

Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity

Published on: September 20, 2024

370

相关实验视频

Last Updated: Jun 7, 2025

Author Spotlight: Exploring Press Needle Efficacy and Underlying Molecular Pathways
05:26

Author Spotlight: Exploring Press Needle Efficacy and Underlying Molecular Pathways

Published on: April 12, 2024

1.3K
Inducement and Evaluation of a Murine Model of Experimental Myopia
07:20

Inducement and Evaluation of a Murine Model of Experimental Myopia

Published on: January 22, 2019

9.8K
Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity
05:46

Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity

Published on: September 20, 2024

370

科学领域:

  • 眼科医生 眼科 眼科
  • 儿科眼科医生 儿科眼科医生
  • 临床研究 临床研究

背景情况:

  • 近视是一种常见的折射误差,在全球范围内正在增加,特别是在儿童中.
  • 渐进的近视会给长期的眼睛健康带来风险,包括视网膜脱落和近视性黄斑病.
  • 有效的干预措施对于减缓儿科患者近视进展至关重要.

研究的目的:

  • 为了评估低剂量氨酸0.01%在控制近视进展方面的疗效.
  • 在24个月内评估轴长度,视敏度,瞳孔大小和适应幅度的变化.
  • 确定阿特罗平0.01%在渐进性近视症中的安全性和成功率.

主要方法:

  • 一项前性研究涉及51名患有渐进近视的儿童和青少年 (3.5-17岁).
  • 治疗包括每天晚上在两只眼睛内注入0.01%的阿特罗平.
  • 测量近视进展,轴长,视敏度,瞳孔直径和适应在基线和每6个月进行2年.

主要成果:

  • 平均近视的进展是0.16 D在12个月和1.28 D在24个月.
  • 12个月的平均轴长增加为0.05毫米,24个月的平均轴长增加为0.69毫米.
  • 在24个月内,近视控制的绝对成功率为70.8%,控制轴长度增长的成功率为58.3%.

结论:

  • 在大多数儿科患者中,Atropine 0.01%显著减缓近视的进展和轴延伸.
  • 该疗法表现出良好的安全性,没有报告任何重大并发症.
  • 低剂量氨酸治疗是治疗儿童和青少年渐进近视的推和有效选择.